MRK Stock Price Today (September 2026) — Merck & Co., Inc. Analysis & Key Metrics 2026-09-04
Merck & Co., Inc. (MRK) is trading at $150.33, down 1.32% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $148.73 (-1.1% upside).
- Volatility remains elevated (48.63% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (5.10% YoY) alongside significant competitive pressures.
MRK Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Merck & Co., Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $412.83B
P/E Ratio
Forward P/E: 15.48
Revenue Growth
Year over Year
Analyst Target
+-1.1% upside potential
Key Investor Questions About MRK
What investors need to know before buying
Based on current market data, MRK presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 61.03)
- Fundamentals say: Caution warranted (high leverage concerns)
MRK's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for MRK investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $53.91B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, MRK stock traded between $77.58 and $156.92—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 48.63% annualized volatility and β=0.42, the stock exhibits low sensitivity to market moves—making MRK suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.
Revolution Medicines Got Its Breakthrough—What Moves It Next?
FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.
Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill?
Merck (NYSE:MRK) received FDA approval for LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor for hypercholesterolemia. The new therapy offers a pill-based alternative to existing injectable PCSK9 treatments for patients with high cholesterol. The approval introduces a new segment in cholesterol management that other drug companies are also targeting with oral PCSK9 candidates. For a broader view of where drug development and data driven medicine intersect, explore other healthcare...
Was JNJ Stock Rally Actually Its Own?
Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty. Total revenue reached $63.7 million for the quarter, up from $47.6 million a year earlier, and Ligand raised the low end of its full-year adjusted earnings […]
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.
Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning
Cipla secured exclusive U.S. commercialization rights to Qilu's proposed biosimilar ahead of Keytruda's expected 2028 patent expiration.
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda.
Explore More Analysis for MRK
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Merck & Co., Inc.
Merck & Co., Inc. (MRK) is currently trading at $150.33. The RSI (14-day) is at 61.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $148.73 implies 1.1% downside from current levels. Volatility is high at 48.6% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Merck & Co., Inc. (MRK): The trailing P/E ratio is 120.26, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 15.48, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 10.26, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 8.85. Price-to-Sales is 5.57. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering MRK, the consensus price target is $148.73. This represents a 1.1% downside from the current price of $150.33. The range spans from a low target of $105.00 to a high target of $186.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Merck & Co., Inc. (MRK) pays a dividend with a current yield of approximately 2.26%. The annualized dividend rate is $3.32 per share. The payout ratio is 268.8%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-09-15T00:00:00.000Z.
Key risks for Merck & Co., Inc. (MRK) investors include: 1. High volatility (48.6% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 128.41) which could pressure margins in a rising rate environment. 3. Elevated short interest (99.0% of float) suggests significant bearish sentiment. 4. Unsustainable dividend payout ratio (269%) could lead to a dividend cut. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Merck & Co., Inc.'s (MRK) current debt and financial health profile: Total debt stands at $53.91B. The debt-to-equity ratio is 128.41, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.32, indicating adequate short-term liquidity. The quick ratio is 0.74. The company holds $7.14B in cash and equivalents. Free cash flow is positive at $15.17B, providing a cushion for debt servicing and shareholder returns.